Results 1 to 10 of about 4,530 (177)
Treatment Approaches for Atypical CIDP [PDF]
Frontiers in Neurology, 2021 The variants of chronic inflammatory demyelinating polyneuropathy (CIDP) differ not just in their clinical, pathological and electrophysiological characteristics, but often in their indifferent response to conventional immunosuppressive agents which are ...
Deepak Menon, Vera Bril, Bril Vera
exaly +5 more sources
The Misdiagnosis of CIDP: A Review [PDF]
Neurology and Therapy, 2020 There is a growing realization that many patients are incorrectly diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP), with at least half of patients that carry a diagnosis of CIDP in the USA possibly having a different explanation for their neuropathy or having no neuropathy at all.
Jeffrey Allen, Allen Jeffrey A
exaly +4 more sources
Clinical features of chronic inflammatory demyelinating polyneuropathy: a single-center experience with 33 patients [PDF]
Frontiers in NeurologyBackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy with heterogeneous clinical presentations. Although several clinical subtypes, including typical and variants, have been described, evidence regarding ...
Toshiya Nomura +2 more
doaj +2 more sources
Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan [PDF]
Frontiers in NeurologyBackgroundEfgartigimod, a neonatal Fc receptor blocker, has received regulatory approval for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Japan in December 2024.AimsTo investigate the effectiveness and safety of ...
Tatsuya Imai +5 more
doaj +2 more sources
Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States [PDF]
Frontiers in NeurologyBackgroundManagement of chronic inflammatory demyelinating polyneuropathy (CIDP) is challenged by heterogeneity in severity, comorbidities, potential adverse effects, and treatment accessibility.
Cécile Blein +8 more
doaj +2 more sources
Practical Neurology, 2022 Chronic inflammatory demyelinating polyneuropathy is a disabling but treatable disorder. However, misdiagnosis is common, and it can be difficult to optimise its treatment. Various agents are used both for first and second line. First-line options are intravenous immunoglobulin, corticosteroids and plasma exchange.
Fehmi, J +4 more
openaire +3 more sources
Cosmetics, 2022 The skin is constantly subject to external stressors (the exposome), including particulate matter and blue light. These can penetrate the deeper layers of the skin, inducing the release of free radicals and triggering an inflammatory cascade of events ...
Vimi Lutchmanen Kolanthan +11 more
doaj +1 more source
Frontiers in Neurology, 2022 ObjectiveTo investigate the contribution of duration and temporal dispersion (TD) of the distal compound muscle action potential (CMAP) in discriminating chronic inflammatory demyelinating polyneuropathy (CIDP) from diabetic sensorimotor polyneuropathy ...
Monica Alcantara +6 more
doaj +1 more source
Clinical Neurophysiology Practice, 2023 Objective: We aimed to evaluate differences in ultrasonographic nerve enlargement sites among typical chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), distal CIDP, multifocal CIDP and multifocal motor neuropathy (MMN) in a Japanese ...
Masaaki Yoshikawa +6 more
doaj +1 more source
CIDP mimics: a case series [PDF]
BMC Neurology, 2021 Abstract Background To report our experience with a group of patients referred for refractory CIDP who fulfilled “definite” electrodiagnostic EFNS criteria for CIDP but were found to have an alternate diagnosis. Methods Patients who were seen between 2017 and 2019 for ...
Orly Moshe-Lilie +5 more
openaire +3 more sources